Genome Medicine | Volume 2 Issue 11

Submit a manuscript Register Contact us Follow us on Twitter

Explore Genome Medicine

Advertisement

Articles

cover

	Volume 2 Issue 11
	Comment
	Commentary Bridging the gap between epigenetics research and nutritional public health interventions Graham C Burdge, Karen A Lillycrop Genome Medicine 2010, 2:80 (5 November 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A poor diet early in life can lead to increased risk of disease, but this may be counteracted by epigenetics, with important implications for nutrition and public health.
	Commentary Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Takayuki Iwamoto, Lajos Pusztai Genome Medicine 2010, 2:81 (12 November 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Why do the many gene signatures which claim to predict breast cancer prognosis vary so much in the genes they contain?
	Musings The $1,000 genome, the $100,000 analysis? Elaine R Mardis Genome Medicine 2010, 2:84 (26 November 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Lowered price and speed brings routine clinical use of whole-genome sequencing ever closer, but improved reference and functional data and dedicated analysis pipelines are required to make it a reality.
	Review
	Minireview Genetic discovery: the prescription for chronic pain Ming Zheng, Gary Peltz Genome Med 2010, 2:82 (15 November 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The first genetic risk factor for chronic pain in humans has been identified as a potassium channel gene and could lead to new developments in pain therapy.
	Review Systems medicine and the integration of bioinformatic tools for the diagnosis of Alzheimer's disease Matej Orešič, Jyrki Lötjönen, Hilkka Soininen Genome Med 2010, 2:83 (15 November 2010) Abstract \| Full text \| PDF \| Editor’s summary Integration of data acquired at the molecular, cell and tissue levels will improve early detection of Alzheimer’s disease and our understanding of its pathology.
	Review The pharmacogenetics of imatinib Stéphanie Dulucq, Maja Krajinovic Genome Med 2010, 2:85 (30 November 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The response to imanitib, a tyrosine kinase inhibitor used to treat various cancers, depends on genetic variation in several enzymes and transporters.
	Review Genomic risk factors in sudden infant death syndrome David W Van Norstrand, Michael J Ackerman Genome Medicine 2010, 2:86 (30 November 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Genetic risk factors are clearly present in sudden infant death syndrome; however, more work is needed to examine the mechanisms for how individual genetic factors truly create infant vulnerability.